Kornimate/medical-research-clean huggingface dataset:
study evaluating the mechanism of action of pf-04965842 monotherapy for moderate-to-severe atopic dermatitis

Conditions: Atopic Dermatitis

Summary: b7451037 is a randomized, double-blind, placebo-controlled, parallel-group, phase 2a study to investigate the mechanism of action of pf-04965842 by correlating efficacy outcomes with changes from baseline in key skin and blood biomarkers in adult participants at least 18 years of age with moderate-to-severe atopic dermatitis. participants will be screened within 28 days prior to the first dose of study intervention to confirm eligibility. a total of approximately 51 participants will be randomized in a 1:1:1 ratio to receive pf-04965842 200 mg once daily (qd), pf004965842 100 mg qd, or matching placebo qd for 12 weeks. at the end of the 12-week study treatment, qualified participants will have the option to enter the long-term extension study b7451015 (nct03422822). participants discontinuing early from this study will undergo a 4-week off-treatment follow-up period.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of chronic moderate-to-severe atopic dermatitis (ad) for at least 1 year * recent history of inadequate response to medicated topical therapy for ad or required systemic therapy to control disease * moderate-to-severe ad defined as affected bsa at least 10%, iga at least 3, easi at least 16, peak pruritus nrs at least 4 exclusion criteria: * a current or past medical history of conditions associated with thrombocytopenia, coagulopathy, or platelet dysfunction * currently have active forms of other inflammatory skin diseases, i.e. not ad, or have evidence of skin conditions (e.g. psoriasis, seborrheic dermatitis, lupus) at the time of day 1 that would interfere with evaluation of ad or response to treatment * participants who have received prior treatment with any systemic jak inhibitors * require treatment with prohibited concomitant medication(s) or have received a prohibited concomitant medication within specified time frames prior to the first dose of study medication, including topical treatments that could affect ad * pregnant or breastfeeding women or sexually-active women of childbearing potential who are unwilling to use contraception

Keywords: atopic dermatitis atopic eczema eczema jak janus kinase
preventing seroma formation after stripping saphenous vein in coronary bypass

Conditions: Coronary Bypass Graft Stenosis of Autologous Vein

Summary: the great saphenous vein is the most commonly used material in coronary vascular bridging operation. coronary bypass operation to obtain the great saphenous vein is mainly through the incision open groin to ankle. this operation may damage the lymphatic, cause lymph circumfluence obstacle, cause fat liquefaction, scar formation, wound dehiscence, around hematoma and other a series of symptoms.based on some studies and our experience that vacuum assisted closure （vac）is effective in complex wound failures following stripping saphenous vein, we use vac to prevent seroma formation after stripping saphenous vein in coronary bypass. this study is aimed to evaluate the efficacy and economics benefits of early vac application on postoperative complications and wound healing after stripping saphenous vein in coronary bypass in comparison to conventional suction drain.


Eligibility criteria:
inclusion criteria: * written informed consent * coronary heart disease patients to transplant more than 2 vascular bridge * the thigh groin following from the saphenous vein exclusion criteria: * subjects does not agree to participate in clinical trials * subjects had a injury, operation history of thigh * subjects having ever received chemotherapy before the surgery * subjects with known hypersensitivity to components of the surgical sticky membrane
dynamic evaluation of covid-19 diagnostic tests

Conditions: COVID-19

Summary: rapid antigenic tests are not yet used in real life. their contribution in the diagnostic strategy based on the gold standard including anamnesis, thoracic ct and pcr has not been evaluated. we propose to compare to the gold-standard defined above, the combination of an sars-cov-2 antigen, anamnesis and thoracic ct for the diagnosis of covid-19 infection.

this is an interventional study comparing gold standard anamnesis, thoracic ct and pcr versus sars-cov-2 antigen, anamnesis and thoracic ct for the diagnosis of covid-19 infection. patients will be sampled for the tests at day 1 and then monitored for symptoms and clinical data and additional test at day 21.

Eligibility criteria:
inclusion criteria: * symptomatic patient with confirmed gold-standard sars-cov-2 (covid-19) infection * presenting at least one criterion for hospitalization: * respiratory failure and oxygenation * circulatory failure (systolic bp \< 90 mmhg) * neurological failure (confusion, drowsiness, altered consciousness) * polypathological terrain and co-morbidities (chronic respiratory failure, heart failure or cardiovascular pathology, renal failure, diabetes, immunosuppression, obesity, cirrhosis) * eligible for different sampling methods * beneficiary of a social insurance scheme or entitled person exclusion criteria: * gold standard not in favour of sars-cov-2 infection (covid 19) * minor patient * refusal to participate * patient under guardianship * patient under guardianship * pregnant or breastfeeding woman
robotic assisted early mobilization in ventilated icu patients

Conditions: Critical Illness Polyneuromyopathy; Critical Illness; Early Ambulation; Rehabilitation

Summary: feasibility trial investigating robotic assisted early mobilization vs. early mobilization in critically ill patients.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * invasive mechanically ventilated and expected to be ventilated for another 24 hours * cardiovascular stability, allowing mobilization * respiratory stability, allowing mobilization exclusion criteria: * bed-bound before icu admission * bed-rest order or contraindication of weight load of the lower extremity or spine * severe skin lesions or fasciitis in the area of contact with the device or rhabdomyolysis * fresh sab, icb or elevated icp * status epilepticus * acute intoxication * shock with catecholamine doses \>0.3µg/kg/min or acute bleeding including organ ruptures * multiorgan failure with lactate \> 4 mmol/l * body height outside the range 150-195 cm * body weight outside the range 45-135 kg * pavk iv° * pacemakers or other electrical stimulators * implanted medical pumps * pregnancy * life expectancy below 7 days or acute palliative care situation * death inevitable or maximum therapy is not carried out by the treating physicians or due to patient's request * unable to understand the official language * icu stay \> 72h at the time of enrolment translated with www.deepl.com/translator (free version)

Keywords: early mobilization pilot trial feasibility trial robotic assisted
the effect of reduced dose of enoxaparin on the outcomes of treatment with enoxaparin

Conditions: Acute Coronary Syndrome; Venous Thromboembolism; Atrial Fibrillation; Hypercoagulability

Summary: we hypothesize that reduced dose of enoxaparin in elderly patients will result in reduced proportion of patients with therapeutic anti xa activity and reduced clinical efficacy.

patients treated with enoxaparin will be followed, sociodemographic , clinical and laboratory data will be collected. clinical efficacy as well as adverse events will be monitored.

Eligibility criteria:
inclusion criteria: * treatment with enoxaparin exclusion criteria: * no

Keywords: bleeding anticoagulation lmwh enoxaparin
the effectiveness of using low-level light therapy to treat sleep and psychological symptoms among shift-work nurses

Conditions: Shift Work Type Circadian Rhythm Sleep Disorder

Summary: the purpose of this study is to explore the treatment of low level light therapy(lllt) mitigate possible insomnia and psychological symptoms, when nurses have taken shifts.the investigators hope that the goal of this interventional research is to improve sleep quality and psychological symptoms of shift nurses in order to promote health.

low-level light therapy; lllt is also called photobiomodulation; pbm, which is a new type of interventional therapy.lllt applies low-level lasers or light-emitting diodes(leds) to the human body for treatment. the wavelength of irradiated light is between red light(630-700 nm) and near-infrared light(700nm-1,100nm), and leads to a positive biological effect. it is a safe, painless, non-invasive treatment method. when lllt is applied to the brain, it can pass through the scalp, head bone and reach the brain, and then stimulating the photochemical reaction in the cells, this is called transcranial low-level laser therapy (t-lllt) or transcranial photobiomodulation(t-pbm). tlllt has existed since 1967, and more than thousands of scientific studies have shown that photons can stimulate biological responses and promote the normal work of cells. t-lllt can treat a variety of diseases, such as emotional symptoms, lower back pain, weight loss, skin anti-aging, wound healing, etc. there are no reports of side effects. the main mechanism is similar to the photosynthesis of plants. it absorbs light and produces chemical reactions, supports mitochondrial function, and significantly increases the production of atp(the main carrier of energy in cells.)in the brain, so as to function work better and achieve self-repair. this research uses dr. tai's energy cap, the manufacturer is topunion globaltek inc., which passed the certification of the ministry of health and welfare(mohw) for medical device in 2019. it has been modified to the second generation and is now on the market. it basically provides two kinds of red light (wavelength of 660nm) and near-infrared light(wavelength of 850nm), which is mainly used at home. the research intervention will be conducted for four weeks, pre-tests and post-tests will be conducted as indicators to evaluating sleep and psychological symptoms.

Eligibility criteria:
inclusion criteria: 1. registered nurses who consciously have insomnia and isi\>=9. 2. people who have clear consciousness, can understand and agree to participate in this research. 3. registered nurses who have been on shifts in the past six months. 4. have the same type of shift within the four weeks. exclusion criteria: 1. those who have undergone head surgery. 2. those who are pregnant.

Keywords: anxiety depression nurses lllt
beta blocker effects in traumatic brain injury

Conditions: Trauma, Brain

Summary: the study will be conducted on polytrauma patient who are admitted from emergency room or postoperative with head trauma to evaluate effects of beta blocker on patients with tbi.

the study will be conducted on polytrauma patient who are admitted from emergency room or postoperative with head trauma . patients will be randomly assigned into two groups by sealed envelope technique into two equal groups. parameters assessment: * length of icu stay * length of total hospital stay * ct scan to exclude another intracranial hemorrhage or increase in hemorrhage * functional status will be assessed using the gcs * hemodynamic data ( bl.p / hr ) * crystalloid volume that patient need in 24h * mortality rate

Eligibility criteria:
inclusion criteria: * gcs preoperative \>10 * abbreviated injury scale (ais) \>3 * length stay in icu \>48 h exclusion criteria: * hypersensitivity to propranolol * asthmatic patient * copd * history of smoking * any cardiac problems eg: ( heart failure or hb ) * pheochromocytoma * pregnant patient * length stay \<48h * death within 48 h of admission * patient who previously received any beta blocker at home. * symptomatic bradycardia \<60 b/m (sick sinus syndrome) * hemodynamic unstable patients
a study of ql1706 or ql1604 in patients with limited-stage small cell lung cancer after chemoradiotherapy.

Conditions: Small-cell Lung Cancer

Summary: the study is being conducted to evaluate the efficacy and safety of ql1706 versus ql1604 monotherapy as consolidation treatment in patients with limited-stage small cell lung cancer (ls-sclc) who have not experienced disease progression after concurrent or sequential chemoradiotherapy. ql1706 (iparomlimab and tuvonralimab) is a single bifunctional mabpair product against pd-1 and ctla-4. ql1604 is a monoclonal antibody against pd-1.


Eligibility criteria:
inclusion criteria: * the patient must be aged between 18 and 75 years (inclusive of boundary values), and both males and females are eligible. * pathologically confirmed ls-sclc \[i-iii stage sclc (any t, any n, m0)\], according to the american joint committee on cancer (ajcc, 8th edition) staging manual. * received 4 cycles of chemotherapy concurrent or sequential with radiotherapy. chemotherapy must contain platinum and etoposide. radiotherapy must be either total 60-70 gy over 6 weeks for the qd regimen or total 45 gy over 3 weeks for bid schedules. * patients must have achieved a complete response (cr), partial response (pr), or stable disease (sd) after receiving curative platinum-based crt and must not have developed progressive disease (pd) prior to study entry. exclusion criteria: * mixed sclc and non-small cell lung cancer (nsclc). * extensive-stage sclc. * active or prior documented autoimmune or inflammatory disorders. * received other chemotherapy regimens besides etoposide and platinum-based therapy. * active or prior documented autoimmune or inflammatory disorders. * presence of interstitial lung disease or active non-infectious pneumonia (excluding grade 1 radiation pneumonitis not treated with corticosteroids).
gciv as an adjuvant therapy for community-acquired severe sepsis or septic shock

Conditions: Severe Sepsis; Septic Shock

Summary: this study is to determine whether the intravenous application of 'ⅳ-globulin s inj. (human immunoglobulin g)' can reduce mortality in patients with severe sepsis or septic shock.

a placebo-controlled, randomized, double-blind, multi-center, phase 3 study to evaluate the efficacy and safety of intravenous administration of 'iv-globulin s inj.(human immunoglobulin g)' as an adjuvant therapy in adult subjects with community-acquired severe sepsis or septic shock.

Eligibility criteria:
inclusion criteria: * patients with severe sepsis or septic shock, if all of the following criteria is satisfied. 1. age ≥ 18 years 2. proved or suspected infection in at least one site * pneumonia * urinary tract infection * intra-abdominal infection * primary bloodstream infection * skin and soft tissue infection 3. three or more of the following * a core temperature ≥ 38° c or ≤ 36° c * a heart rate ≥ 90 beats/min * a respiratory rate ≥ 20 breaths/min or paco2 ≤ 32 mmhg or use of mechanical ventilation for an acute process * a white blood cell count ≥ 12000/mm3 or ≤ 4000/ mm3 or immature neutrophils \> 10% 4. acute organ failure in one or more of the following * kidney * respiratory system * blood system * metabolic system * circulatory system 5. apache score ≥ 20 and ≤ 29 6. patient can treatment with gciv in icu within at least 48 hours 7. informed consent exclusion criteria: 1. pregnant or breast-feeding women 2. a weight \> 100kg 3. discharged from the hospital at least 14 days prior to new admission 4. transferred from another hospital staying more than 48 hours 5. allergy or shock of ivig 6. treated with ivig within the 12 weeks immediately preceding enrolment in this study 7. iga deficiency 8. hypernatremia or hyperhydration 9. proved or suspected hiv or aids patients(cd4+ \<200ml) 10. current participation in any study within the last 4 weeks 11. do not resuscitate (dnr) status 12. patient's death is considered imminent due to coexisting disease 13. physicians decision to exclude patients from this protocol 14. immunocompromised patients

Keywords: human immunoglobulin g sepsis septic shock
comparison of biodentine and mta pulpotomies in the primary molar teeth 3 year follow up

Conditions: Pulpotomy; Dental Caries

Summary: the aim of this study is to compare two pulpotomy medicaments in primary molars clinically.a total of 200 primary molars with deep caries were treated with two different pulpotomy medicaments (mineral trioxide aggregate and biodentinetm) in this study. the inclusion criteria for tooth selection were no clinical and radiographic evidence of pulp pathology. during 36 months of follow-up at 3-month intervals, clinical and radiographic success and failures were recorded.


Eligibility criteria:
inclusion criteria: * no clinical and radiographic evidence of pulp pathology, * no clinical and radiographic symptoms, * no history of spontaneous pain and tenderness, * no percussion, swelling or sinus tracts and pathologic mobility. exclusion criteria: * any clinical or radiographic evidence of pulp degeneration (spontaneous or nocturnal tooth pain, tenderness to percussion, pathological mobility, internal or external root resorption, swelling or fistula, widened periodontal ligament (pdl) * furcal or periapical radiolucency teeth requiring more than 5 minutes to achieve hemostasis during clinical procedure. * without permanent successor

Keywords: pulpotomy pediatric dentistry primary molars
phase-3 study of asp7374, cell-culture-derived influenza vaccine

Conditions: Influenza

Summary: the purpose of this study is to compare immunogenicity and safety of asp7374 (cell-culture derived influenza vaccine) with those of approved egg-derived trivalent inactivated vaccine (tiv) in elderly subjects.


Eligibility criteria:
inclusion criteria: * medically stable, as judged on the basis of history and concurrent diseases * subject understands procedure of the protocol and is willing to comply with the protocol exclusion criteria: * scheduled to receive another vaccine during the study * received influenza ha vaccine within 180 days prior to screening * received or scheduled to receive a live vaccine within 28 days prior to vaccination with the study vaccine, and received or scheduled to receive an inactivated vaccine or a toxoid within 7 days prior to vaccination with the study vaccine * diagnosis of immune deficit in the past, has a family member (within the third degree of kinship) with a diagnosis of congenital immunodeficiency syndrome * received one of the following medications or treatment prior to vaccination with the study vaccine: interferon formulation, drugs which affect the immune system, corticosteroids, g-csf, m-csf, human immunoglobulin products, blood products * history of anaphylactic shock or an allergic reaction such as generalized eruption due to food or drug (including vaccines) allergies, fever ≥39.0°c within 2 days after the previous vaccination (influenza vaccine and others) * history of seizures * history of guillain-barre syndrome or acute disseminated encephalomyelitis (adem) * confirmed diagnosis of influenza within 84 days prior to screening test * body temperature of ≥37.5°c on day 1 (before vaccination) * immunological tests reveal positive hbs antigen, hcv antibody, and hiv antigen and/or antibody

Keywords: influenza vaccine
resist-2: 2nd-line art for hiv-2 infection

Conditions: HIV-2 Infection

Summary: prospective, longitudinal, open label, hiv-2 viral load and antiretroviral resistance informed 2nd-line arv implementation study.

prospective, longitudinal, open label, hiv-2 viral load and antiretroviral resistance informed 2nd-line arv implementation study. duration up to 3 years sample size 150 population hiv-2-infected adults (≥18 years old); arv-experienced, with virologic failure on 1st-line 2nrti+lpv/r in the isaarv program. stratification by arv resistance regimen or intervention intervention: implement real time arv resistance testing using rapid dbs/cs arv regimens: based on arv resistance testing 1. no resistance: current art: zidovudine 300mg bid + lamivudine 150mg bid or tenofovir df 300mg qd + lamividine 300mg qd or emtricitabine 200mg qd + lopinavir/ritonavir 400/100mg bid (azt/3tc or tdf/3tc or tdf/ftc + lpv/r) +enhanced adherence counseling 2. nrti resistance only: tenofovir df 300mg qd + lamividine 300mg qd or emtricitabine 200mg qd + lopinavir/ritonavir 400/100mg bid + raltegravir 400mg bid (tdf/ftc or tdf/3tc + lpv/r + ral) + enhanced adherence counseling 3. nrti-pi resistance: tenofovir df 300mg qd + lamividine 300mg qd or tenofovir df 300mg qd + emtricitabine 200mg qd + darunavir 600mg bid-ritonavir 100mg bid + raltegravir 400mg bid (tdf/ftc or tdf/3tc +drv/r2 + ral) + enhanced adherence counseling

Eligibility criteria:
inclusion criteria: 1. hiv-2 infection: confirmed by determine (alere, inc.) \& immunocomb ii (alere, inc.) or equivalent 2. failing 1st line antiretroviral therapy (e.g. azt/3tc or tdf/xtc + lpv/r; previous 3 nrti or 2 nrti regimens; previous indinavir (idv) use, current or previous atazanavir (atv) use; previous nnrti use) 3. for females of reproductive potential: negative serum or urine pregnancy test 4. men and women age \>/=18 years 5. ability and willingness of subject to provide informed consent exclusion criteria: 1. hiv-1 or hiv-1/hiv-2 dual infection 2. pregnancy or breast-feeding 3. lab abnormalities * ast/alt \>2.5 x uln * crcl \<30 4. current or previous use of integrase inhibitors or darunavir
antigravity treadmill training on gait characteristics and balance

Conditions: Burns

Summary: severe burn injuries are associated with hypermetabolic responses and increased catabolism. these generalized changes lead to a vast loss of muscle mass and cause reduced muscle strength and endurance, limited walking ability, and reduced functional mobility recently, the antigravity treadmill or lower body positive pressure (lbpp) technology has been developed as a unique system of maintaining a participant's body weight all through treadmill training and developing low-load treadmill walking using a unique treadmill system that allows gaining the benefits of low-load treadmill walking without interrupting with locomotion dynamics

objective: this single-blind randomized controlled trial aimed to examine the effects of antigravity treadmill training on gait characteristics and balance in healed adult burned patients. methods: fifty-five adult burn patients were chosen to participate in this study, their ages ranged from 18 to 35 years. they were randomly allocated to alter g (alg) (n=22), and control (cont) (n=23) groups. the control group received a traditional physical therapy program (tptp), three times per week. in contrast, the experimental group received antigravity treadmill training (30 minutes,3 times/week, speed 0.1 m/sec, 75% body weight) in addition to the traditional physical therapy program given to the control group. all study participants followed the instructions recommended for the exercise performed (three days per week) in terms of intensity, type, and duration to limit any difference between groups, as well as instructions about not exercising the rest of the week. during the study period, both groups received standard medical care. outcome measures: gait characteristics and postural stability indices were measured at the baseline (pre) and end of 12 weeks of intervention (post). the statistical package for the social sciences (spss) software was used for statistical analysis. the shapiro-wilk test was used to determine the normality of the data. the paired t-test was used to test within-group comparisons of mean changes in muscle strength, gait characteristics, and postural stability indices. the unpaired t-test was used to compare between groups. p\<0.05 was chosen as the level of significance.

Eligibility criteria:
inclusion criteria: * patients with circumferential lower limb deep second to third-degree thermal injury * burns extending from the lower trunk to the foot were considered * the total body surface area (tbsa) ranges from 35 to 50% * all patients completed the same physical therapy program during hospitalization peroid exclusion criteria: * lower limb prosthesis * severe musculoskeletal disorders * serious cardiovascular insult * participation in an outside physical training program * fracture * medication that negatively impacts the study's results * brain injury * vestibular disorders * visual disorders * history of epilepsy

Keywords: burn gait balance antigravity treadmill